

Brilliant Violet 605™ anti-human CD194 (CCR4)

Catalog # / Size: 2397085 / 25 tests
2397090 / 100 tests

Clone: L291H4

Isotype: Mouse IgG1, κ


Immunogen: Human CCR4 transfected cells

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific




Human peripheral blood lymphocytes were stained with CD3 FITC and CD194 (clone L291H4) Brilliant Violet 605™ (top) or mouse IgG1, κ Brilliant Violet 605™ isotype control (bottom).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research

purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Description: CD194, also known as CCR4, is a CC chemokine receptor. It binds CCL17 and CCL22 and is expressed on a subset of T and B cells, basophils, monocytes, and NK cells. Human Th2 cells are characterized by the expression of CCR4 and CCR8, and these receptors are regulated differently during Th2 development. Human peripheral blood Tregs can be divided into two distinct populations based on the expression of CCR4. Freshly isolated Tregs express CCR4 and presumably represent memory-type Tregs, and CCR4⁻ Tregs require CD3-mediated activation to acquire a regulatory activity. Depletion of CCR4⁺ T cells leads to Th1-type polarization of CD4⁺ T cells and augmentation of CD8⁺ T cell responses to tumor antigens. CCR4 and its ligands are important for the recruitment of memory T cells into the skin in various cutaneous immune diseases.

Antigen
References:

1. Katschke KJ, *et al.* 2001 *Arthritis Rheum.* 44:1022.
2. Colantonio L, *et al.* 2002 *Eur. J. Immunol.* 32:1264.
3. Jakubzick C *et al.* 2004 *Am. J. Pathol.* 165:1211.
4. Morimoto Y, *e*